| Literature DB >> 24895589 |
Md Akil Hossain1, Ji-Yong Park2, Jin-Yoon Kim1, Joo-Won Suh3, Seung-Chun Park1.
Abstract
Salmonellosis is a common and widely distributed food borne disease where Salmonella typhimurium is one of the most important etiologic agents. The purpose of this study was to investigate the antimicrobial activity of Nymphaea tetragona alone and in combination with antibiotics against S. typhimurium. It also aimed to assess the plant for quorum sensing inhibition (QSI) activity and to identify the bioactive compounds. The antibacterial activities of the extract were assessed using broth microdilution method. Disk agar diffusion method was employed to determine the QSI and bioactive compounds were identified by GC-MS analysis. Ethyl acetate fraction of N. tetragona extract (EFNTE) demonstrated good antimicrobial activity (MIC 781 μg/mL) against 4 strains out of 5. FIC index ranged from 0.375 to 1.031 between EFNTE/tylosin and 0.515 to 1.250 between EFNTE/streptomycin against S. typhimurium. Among all extracts, EFNTE and butanol fraction more significantly inhibited pigment production of C. violaceum. Polyphenols were identified as major compound of EFNTE and butanol fraction. These results indicate that combination among N. tetragona extract and antibiotics could be useful to combat drug-resistance Salmonella infections and polyphenols are promising new components from N. tetragona that warrant further investigation as a candidate anti-Salmonella agent and quorum sensing inhibitor.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24895589 PMCID: PMC4033391 DOI: 10.1155/2014/562173
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
List of Salmonella strains used in this study along with their sources and sensitivities against commercial antibiotics.
| Antimicrobials | Concentration ( | KCTC2515 | Isolates | |||
|---|---|---|---|---|---|---|
| ST171 (chicken) | ST482 (pig) | ST688 (cattle) | ST21A (pig) | |||
| Chloramphenicol | 30 | S | S | S | R | S |
| Ciprofloxacin | 5 | S | S | S | S | S |
| Erythromycin | 15 | R | R | R | R | R |
| Gentamycin | 10 | S | R | S | R | R |
| Kanamycin | 30 | S | S | R | R | I |
| Norfloxacin | 10 | S | S | S | S | S |
| Streptomycin | 10 | I | R | R | R | R |
| Tetracycline | 30 | S | R | R | R | S |
Antibiotic sensitivity is considered according to the zone diameter interpretative standards of CLSI [26]. R: resistant; I: intermediate, and S: sensitive.
Antimicrobial activity of NTME and its solvent fractions against five strains of Salmonella typhimurium.
| KCTC 2515 | ST171 | ST482 | ST688 | ST21A | |
|---|---|---|---|---|---|
| MIC ( | |||||
| NORa | 0.063 | 0.063 | 0.125 | 0.063 | 0.125 |
| NTME | 6250 | 6250 | 6250 | 6250 | 6250 |
| DFNTE | >2500 | >2500 | >2500 | >2500 | >2500 |
| EFNTE | 781 | 781 | >781 | 781 | 781 |
| BFNTE | 6250 | 6250 | 6250 | 6250 | 6250 |
| MBC ( | |||||
| NORa | 1 | 1 | 1 | 1 | 1 |
| NTME | 12500 | 12500 | 25000 | 12500 | 12500 |
| DFNTE | >2500 | >2500 | >2500 | >2500 | >2500 |
| EFNTE | 1562 | 1562 | 1562 | 1562 | 1562 |
| BFNTE | 25000 | 25000 | 25000 | 25000 | 25000 |
NOR: norfloxacin, NTME: N. tetragona 50% methanol extract, EFNTE: ethyl acetate fraction of N. tetragona 50% methanol extract, DFNTE: dichloromethane fraction of N. tetragona 50% methanol extract, BFNTE: butanol fraction of N. tetragona 50% methanol extract. aPositive control.
Figure 1Time-kill curves of S. typhimurium KCTC 2515 after treatment with EFNTE at 0.25 × MIC (※), 0.50 × MIC (×), 1 × MIC (▲), and 2 × MIC (■). Ca-MHB was used as a control (◆). The results are presented as mean ± standard deviations (n = 3), and the coefficients of variation for all concentrations are ≤5%.
Figure 2Double disk synergy of EFNTE with commercial antibiotics against S. typhimurium KCTC 2515. EAF: ethyl acetate fraction of N. tetragona 50% methanol extract; TMR: trimethoprim; NOR: norfloxacin; MAR: marbofloxacin; AMP: ampicillin; STR: streptomycin; and TYL: tylosin. Red arrows indicate synergistic interactions.
Fractional inhibitory concentration (FIC) and FIC index (FICI) of combination between tylosin and EFNTE.
| Tylosin | EFNTE | FICI | Interpretation | ||
|---|---|---|---|---|---|
|
Conc ( | FIC of drug A | Conc ( | FIC of drug B | (FIC of A + FIC of B) | |
| 1024 | MIC of A | 0 | MIC of A | MIC of A | MIC of A |
| 1024 | 1 | 6 | 0.0077 | 1.008 | IND |
| 1024 | 1 | 12 | 0.0154 | 1.015 | IND |
| 1024 | 1 | 24 | 0.0307 | 1.031 | IND |
| 512 | 0.5 | 49 | 0.063 | 0.563 | ADI |
| 256 | 0.25 | 98 | 0.125 | 0.375 | SYN |
| 256 | 0.25 | 195 | 0.25 | 0.499 | SYN |
| 128 | 0.125 | 391 | 0.5 | 0.626 | ADI |
| 64 | 0.0625 | 391 | 0.5 | 0.563 | ADI |
| 0 | MIC of B | 781 | MIC of B | MIC of B | MIC of B |
EFNTE: ethyl acetate fraction of N. tetragona 50% methanol extract; Conc: concentration; drug A: tylosin; drug B: EFNTE; SYN: synergistic effect; ADI: additive effect; IND: indifferent effect; MIC: minimum inhibitory concentration. The FICI was interpreted as follows: synergistic effect (0 < FICI ≤ 0.5), additive effect (0.5 < FICI ≤ 1), and indifferent effect (1 < FICI ≤ 4).
Fractional inhibitory concentration (FIC) and FIC index (FICI) of combination between streptomycin and EFNTE.
| Streptomycin | EFNTE | FICI | Interpretation | ||
|---|---|---|---|---|---|
| Conc ( | FIC of drug A | Conc ( | FIC of drug B | (FIC of A + FIC of B) | |
| 32 | MIC of A | 0 | MIC of A | MIC of A | MIC of A |
| 32 | 1 | 6 | 0.0077 | 1.008 | IND |
| 16 | 0.5 | 12 | 0.0154 | 0.515 | ADI |
| 16 | 0.5 | 24 | 0.0307 | 0.531 | ADI |
| 16 | 0.5 | 49 | 0.063 | 0.563 | ADI |
| 16 | 0.5 | 98 | 0.125 | 0.625 | ADI |
| 16 | 0.5 | 195 | 0.25 | 0.75 | ADI |
| 16 | 0.5 | 391 | 0.5 | 1 | IND |
| 8 | 0.25 | 781 | 1 | 1.25 | IND |
| 4 | 0.125 | 781 | 1 | 1.125 | IND |
| 2 | 0.0625 | 781 | 1 | 1.063 | IND |
| 0 | MIC of B | 781 | MIC of B | MIC of B | MIC of B |
EFNTE: ethyl acetate fraction of N. tetragona 50% methanol extract; Conc: concentration; drug A: streptomycin; drug B: EFNTE; ADI: additive effect; IND: indifferent effect; MIC: minimum inhibitory concentration. The FICI was interpreted as follows: synergistic effect (0 < FICI ≤ 0.5), additive effect (0.5 < FICI ≤ 1), and indifferent effect (1 < FICI ≤ 4).
Figure 3Combination interaction of EFNTE with (a) tylosin and (b) streptomycin against S. typhimurium KCTC 2515 by checkerboard microdilution method. Ash colors indicate bacterial growth and without color zones are free of bacteria. EFNTE: ethyl acetate fraction of N. tetragona 50% methanol extract; TYL: tylosin; STR: streptomycin; SYN: synergistic effect; ADI: additive effect; IND: indifferent effect; MIC: minimum inhibitory concentration.
Quorum sensing inhibition activity (as pigment inhibition zone diameters) of Nymphaea tetragona 50% methanol extract and solvent fractions of the crude extract against C. violaceum.
| Solvent fraction/antibiotic | Concentration | Pigment inhibition diameter (mm) |
|---|---|---|
| ( | Mean ± SD | |
| Tetracycline | 10 | 16.33 ± 0.58* |
| Furanone | 100 | 16.67 ± 0.58a |
| Normal Saline | — | ND |
| NTME | 600 | 13.67 ± 1.15c |
| DFNTE | 600 | 13.33 ± 0.58c |
| EFNTE | 600 | 14.67 ± 1.15b |
| BFNTE | 600 | 14.33 ± 1.53b |
NTME: N. tetragona 50% methanol extract, DFNTE: dichloromethane fraction of N. tetragona 50% methanol extract, EFNTE: ethyl acetate fraction of N. tetragona 50% methanol extract, BFNTE: butanol fraction of N. tetragona 50% methanol extract. *Diameter of clear zone. ND: no activity detected. Data shown represent the mean ± SD of three replicates. Different alphabets indicate significant difference.
Major compound list of three solvent fractions according to their contribution in respective solvent and compounds were listed followed by their elution order including reported activity.
| RT | % area | Compound | Activity | Reference |
|---|---|---|---|---|
| Dichloromethane fraction of | ||||
| 35.46 | 3.18 | Heneicosan | — | |
| 37.12 | 5.44 | Tetracosan | — | |
| 38.71 | 7.9 | Pentacosan | — | |
| 40.24 | 11.18 | Hexacosan | Antimicrobial effects | [ |
| 41.71 | 10.57 | Heptacosan | Antifungal activity | [ |
| 43.14 | 8.19 | Octacosan | Antimicrobial effects | [ |
|
| ||||
| Ethyl acetate fraction of | ||||
| 14.37 | 5.9 | 6,8-Dimethylbenzocyclooctene | — | |
| 15.79 | 20.61 | Pyrogallol | Antibacterial, QS inhibition, and potent tyrosinase inhibitor. | [ |
| 16.79 | 1.31 | 1,4-Cyclohexanedicarboxylic acid, 2,5-dioxo-diethyl ester | Anticolon cancer. | [ |
| 26.90 | 1.39 | 1-[7′-Methylbenzofuran-2′-carbonyl]-3-ethylazulene | Derivatives have antibacterial, antifungal, anti-inflammatory, analgesic, antidepressant, anticonvulsant, antitumor, anti-HIV, antidiabetic, antitubercular activity. | [ |
| 27.65 | 70.44 | Methyl gallate | Antimicrobial | [ |
|
| ||||
| Butanol fraction of | ||||
| 12.86 | 57.61 | 2-Hydrazinoquinoline | — | |
| 15.8 | 22.09 | Pyrogallol | Antibacterial, QS inhibition, and potent tyrosinase inhibitor. | [ |
| 27.39 | 12.77 | Methyl gallate | Antibacterial | [ |
Figure 4Gas chromatography coupled with mass spectroscopy (GC-MS) chromatogram of EFNTE and chemical structure of major compounds.